Diabetic Neuropathy Market Scope, Share Analysis And Growth 2025

Whether you're expanding or optimizing within the diabetic neuropathy industry, this report offers the clarity and context needed for confident decision-making.

What Is The Current Outlook For The Diabetic Neuropathy Market?
The diabetic neuropathy market size has grown strongly in recent years. It will grow from $5.79 billion in 2024 to $6.21 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to rising global diabetes prevalence, increased awareness and diagnosis, advancements in diabetic care, growing healthcare expenditure, research and development investments, patient education initiatives.

The diabetic neuropathy market size is expected to see rapid growth in the next few years. It will grow to $9.15 billion in 2029 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to advancements in neuroimaging, patient-centric care approaches, expansion of clinical trials, continued rise in diabetes cases, precision medicine approaches, expansion of regenerative medicine, patient advocacy and support programs. Major trends in the forecast period include collaborative efforts in medical research, digital health solutions, advancements in diagnostic technologies, neuroprotective therapies, personalized treatment strategies, integration of artificial intelligence.

Get your free sample today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9057&type=smp

What Are The Driving Factors Impacting The Diabetic Neuropathy Market?
The rising prevalence of diabetes is expected to boost the growth of the diabetic neuropathy market going forward. Diabetes is a persistent disorder where the body struggles to use and store glucose appropriately (a type of sugar). Diabetes occurs when the body either does not create enough insulin (a hormone that aids in blood sugar regulation) or does not use insulin effectively. Diabetic neuropathy is a type of nerve injury that can occur in diabetics with d different forms of nerve damage causing different symptoms. For instance, in August 2022, according to the IDF Diabetes Atlas report published by the International Diabetes Federation, a Belgium-based global diabetes community and an umbrella organization of over 230 national diabetes associations, 6.7 million deaths were attributed to diabetes in the year 2021, which is equivalent to one death every five seconds. There are currently 537 million adults (aged 20–79) living with diabetes, or 1 in 10 people. It is estimated that this number will increase to 643 million by 2030 and 783 million by 2045. Therefore, the rising prevalence of diabetes is driving the growth of the diabetic neuropathy market.

Analysis Of Major Segments Driving The Diabetic Neuropathy Market Growth
The diabetic neuropathymarket covered in this report is segmented –

1) By Disorder: Peripheral Neuropathy; Autonomic Neuropathy; Proximal Neuropathy; Focal Neuropathy
2) By Drug Class: Analgesics; Anti-Depressants; Anti-Convulsants; Other Drug Classes
3) By Treatment: Drug Treatment; Radiotherapy; Physiotherapy; Other Treatments
4) By Distribution Channel: Online Distribution; Offline Distribution
5) By End-User: Hospitals; Specialty Clinics; Other End-Users

Subsegments:
1) By Peripheral Neuropathy: Distal Symmetric Neuropathy; Mononeuropathy; Polyneuropathy
2) By Autonomic Neuropathy: Cardiovascular Autonomic Neuropathy; Gastrointestinal Autonomic Neuropathy; Genitourinary Autonomic Neuropathy
3) By Proximal Neuropathy: Diabetic Amyotrophy; Lumbosacral Plexus Neuropathy
4) By Focal Neuropathy: Cranial Neuropathy; Cervical Radiculopathy; Other Focal Neuropathies

What Are The Upcoming Trends Of Diabetic Neuropathy Market In The Globe?
Major companies operating in the diabetic neuropathy market are innovating advanced products, such as the neuromodulation therapy device, to enhance treatment options for patients suffering from chronic pain associated with diabetic neuropathy. Neuromodulation therapy devices for diabetic neuropathy offer non-invasive treatment options by modulating nerve activity to relieve pain, improve nerve function, and promote healing in patients with diabetic nerve damage. For instance, in January 2024, Neuralace Medical, Inc., a US-based company that provides non-drug pain management treatment, received approval from the Food and Drug Administration (FDA), a US-based federal agency for Axon Therapy for Chronic Painful Diabetic Neuropathy. Axon Therapy device is designed to treat chronic painful diabetic neuropathy (CPDN). This innovative therapy utilizes neuromodulation techniques to provide relief from pain associated with diabetic neuropathy, marking a significant advancement in pain management options for patients suffering from this condition. The clearance underscores the device's safety and efficacy, allowing Neuralace to move forward with commercialization and expand access to effective treatment solutions for those affected by CPDN.

Which Are The Top Players Involved In Diabetic Neuropathy Market?
Major companies operating in the diabetic neuropathy market include Pfizer Inc., Eli Lilly and Company, Daiichi Sankyo Company Limited, Johnson & Johnson, Depomed Inc., F. Hoffmann-La Roche AG, NeuroMetrix Inc, Lupin Limited, Novartis AG, Boehringer Ingelheim, Regenacy Pharmaceuticals Inc., Merck & Co. Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Merck KGaA, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Zydus Cadila, Biogen Inc., Genentech Inc.

View the full diabetic neuropathy market report here:
https://www.thebusinessresearchcompany.com/report/diabetic-neuropathy-global-market-report

Which Region Drives The Most Demand In The Diabetic Neuropathy Market?
North America was the largest region in the diabetic neuropathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the diabetic neuropathy market during the forecast period. The regions covered in the diabetic neuropathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Contact Us:

The Business Research Company

https://thebusinessresearchcompany.com/

Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267

Email: info@tbrc.info


Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company